Relationship Between Plasma Adiponectin, Retinol-Binding Protein 4 and Uric Acid in Hypertensive Patients With Metabolic Syndrome by Park, Chan Seok et al.
198
Print ISSN 1738-5520 / On-line ISSN 1738-5555
Copyright © 2011 The Korean Society of Cardiology
ORIGINAL ARTICLE
DOI 10.4070/kcj.2011.41.4.198
Open Access
Relationship Between Plasma Adiponectin, Retinol-Binding Protein 4
and Uric Acid in Hypertensive Patients With Metabolic Syndrome
Chan Seok Park, MD, Sang-Hyun Ihm, MD, Hun-Jun Park, MD, Woo-Seung Shin, MD,  
Pum-Jun Kim, MD, Kiyuk Chang, MD, Hee-Yeol Kim, MD, Ho-Joong Youn, MD,  
Wook-Sung Chung, MD, Ki Bae Seung, MD, and Jae-Hyung Kim, MD
Department of Cardiology, College of Medicine, The Catholic University of Korea, Bucheon St. Mary’ Hospital, Bucheon, Korea
ABSTRACT
Background and Objectives: Adipokines have been suggested for their potential use in tracking the clinical progress in the 
subjects with metabolic syndrome (MS). To investigate the relationship between the serum levels of adipokines {adiponectin 
and retinol-binding protein 4 (RBP4)} and the serum level of uric acid in hypertensive (HTN) patients with MS. Subjects and 
Methods: In this study, 38 totally untreated HTN patients were enrolled. Anthropometric measurements, blood pressure 
(BP) were taken in the 12 HTN patients without MS and the 26 HTN patients with MS. Fasting blood samples were collected 
for measurement of adiponectin, RBP4, nitric oxide (NO), glucose, creatinine, uric acid, lipid profile and insulin. Results: The 
HTN with MS group had significant higher values of body mass index, waist length, serum uric acid and triglyceride levels 
than the HTN without MS group. Compared to the HTN without MS group, the HTN with MS group showed significantly 
lower adiponectin (p=0.030), NO (p=0.003) and high density lipoprotein levels (p<0.001). Serum adiponectin levels negatively 
correlated with insulin level (R=-0.453, p=0.026) and uric acid level (R=-0.413, p=0.036), and serum RBP4 levels positively 
correlated with uric acid level (R=0.527, p=0.006) in the HTN with MS group. Multiple linear regression analysis using RBP4 
and adiponectin levels as the dependent variables showed that uric acid level correlated with serum RBP4 level (p=0.046) 
and adiponectin level (p=0.044). Conclusion: The HTN with MS group showed a correlation with two types of adipokines 
(adiponectin, RBP4) and uric acid. Adiponectin, RBP4 and uric acid may be important components associated with MS, es-
pecially when associated with hypertension. (Korean Circ J 2011;41:198-202)
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Introduction 
Metabolic syndrome (MS), that is the clustering of abnor-
malities in glucose metabolism, lipid metabolism, and blood 
pressure (BP),
1) and is associated with an increased preval-
ence of subclinical damage in a variety of organs. MS increa-
ses the risk for the target organ damage in hypertensive (HTN) 
patients
2) and the development of type 2 diabetes mellitus.
3)
Hyperuricemia mediates the development of end-organ da-
mage such as increased carotid intima-media thickness,
4) and 
it is regarded as a cardiovascular risk factor and a determinant 
of MS,
5) although the other studies have concluded that an 
association between serum uric acid and cardiovascular dis-
ease merely reflects the link between serum uric acid and other 
risk factors.
6)
Adiponectin is known to have anti-inflammatory and anti-
atherogenic activities
7) and adiponectin levels significantly 
correlated with various indices (including serum uric acid) of 
MS.
8) Circulating levels of retinol-binding protein-4 (RBP4) 
are elevated in humans with insulin resistance, which is a hall-
mark of MS. It can also predict early stages in the development 
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as cardiovascular disease.
9) Impairment of nitric oxide (NO) re-
lease is associated with endothelial dysfunction.
10)
In this study, we screened the metabolic parameters, renal 
involvement, uric acid, adiponectin, RBP4, NO and insulin 
in HTN patients with or without MS. We investigated the 
relationship between the plasma levels of adiponectin and 
RBP4 with the other variables of MS in the HTN with MS gr-
oup. Finally, we also clarified the association between the two 
types of adipokines (adiponectin, RBP4) and uric acid, which 
are the known markers of endothelial dysfunction and car-
diovascular damage in MS, in the HTN with MS group.
Subjects and Methods
Patients 
In total, seventy consecutive patients diagnosed with essen-
tial hypertension were enrolled from the outpatient clinic at 
Bucheon St. Mary’s Hospital, Bucheon, South Korea. Hyper-
tension was defined as official systolic BP ≥140 mmHg or dia-
stolic BP ≥90 mmHg. These patients had no history of anti-
hypertensive and anti-diabetic treatment and they had not 
taken lipid lowering agents within the last 6 months. The main 
exclusion criteria were: the presence of clinical or laboratory 
evidence of congestive heart failure, atrial fibrillation, previ-
ous stroke, significant valvular heart disease, previous myo-
cardial infarction, history of coronary bypass, secondary cau-
se of hypertension, and neoplastic disease. The patients in-
formed consent had been obtained during the initial visit. 
The patients were categorized into two groups: HTN with-
out MS group and HTN with MS group. The study protocol 
was approved by the Ethics Committee of Bucheon St. Mary’s 
Hospital. 
Definition of metabolic syndrome
MS was diagnosed when two or more of the following cri-
teria were present in the HTN patients: abdominal obesity 
(waist circumference >90 cm and >80 cm in women),
11) hyper-
triglyceridemia (>150 mg/dL), reduced high density lipopro-
tein-cholesterol (HDL-C) (<40 mg/dL in men and <50 mg/dL 
in women), high fasting blood glucose (≥100 mg/dL).
1)
Official blood pressure measurement
BP was measured by nurses during two different visits to 
the outpatient clinic by using a mercury sphygmomanometer. 
At each visit, three measurements were taken at 1-minute in-
tervals after the subject had rested for 5 minutes in the sitting 
position, and the average of the measurements was considered.
Laboratory methods
Blood samples were obtained from the subjects by venipu-
ncture and were placed into ethylenediaminetetraacetic acid-
containing tubes, the samples were centrifuged to obtain se-
rum; the serum was stored at -70°C. Serum adiponectin levels 
were determined using a commercially available enzyme-link-
ed immunosorbent assay (ELISA) kit (R&D Systems, Inc., 
Minneapolis, MN, USA) with a detection limit of 0.1 ng/mL. 
Serum RBP4 concentration was measured by a commercially 
available ELISA according to the manufacturer’s instructions 
(AdipoGen Inc., Seoul, Korea). NO levels were measured us-
ing a commercial kit supplied by BioAssay Systems (Hayward, 
CA, USA), which uses metallic cadmium beads to convert ni-
trates into nitrites. The quantitative insulin sensitivity check 
index (QUICKI) of insulin sensitivity was calculated from the 
fasting insulin and fasting glucose values: QUICKI=1/{log 
(fasting insulin)+log (fasting glucose)} as described by Katz 
et al.
12)
Statistics
The results are expressed as means±standard deviation. 
Comparisons of the serum markers between the HTN with 
MS and the HTN without MS groups were analyzed by using 
the independent t-test. Nonparametric test was also perform-
ed using Mann-Whitney test. Correlations between the levels 
of adiponectin, RBP4, NO and uric acid were also analyzed us-
ing the Pearson correlation test. Several multiple linear re-
gression models were also performed by using plasma adipo-
nectin, RBP4 or NO as the dependent variable and using age, 
body mass index (BMI), creatinine, total cholesterol, QUI-
CKI, and uric acid level as independent variables in the HTN 
with MS group. All statistical calculations were performed 
using a commercially available statistical package (SAS, ver-
sion 8.0, NC). A value of p<0.05 was considered statistically 
significant.
Results
Of the seventy consecutive HTN patients, 26 patients were 
categorized into HTN with MS group. Considering for age 
and sex, 12 patients were selected from the remaining 44 pa-
tients and they were categorized into HTN without MS group. 
Only BMI and waist circumference were significantly higher 
in the HTN with MS group. Serum adiponectin (HTN with-
out MS : HTN with MS=8.57±6.58 : 4.53±4.31, p=0.030) and 
NO (HTN without MS : HTN with MS=61.2±36.0 : 27.5± 
22.5, p=0.003) concentrations were lower in the HTN with 
MS group. Serum levels of RBP4 were elevated in the HTN 
with MS group, although this was not statistically significant 
(HTN without MS : HTN with MS=21.3±12.6 : 38.4±29.7, 
p=0.106). Serum levels of uric acid were higher in both the 
patient groups (HTN without MS : HTN with MS=4.13± 
1.26 : 5.03±1.19, p=0.040). Triglyceride levels were elevated 
and HDL-C levels were reduced in the HTN with MS group 
(Table 1). 200   Metabolic Biomarkers Complicating Hypertension
Relationship between classical and novel 
biomarkers in hypertensive patients with 
or without metabolic syndrome 
Correlation between two adipokines, uric acid and NO are 
summarized in Table 2. In the HTN with MS group, serum 
adiponectin levels were negatively correlated with uric acid 
(r=-0.413, p=0.036) (Fig. 1) and insulin levels (r=-0.453, p= 
0.026) and positively with QUICKI (r=0.442, p=0.031). RBP4 
levels showed positive correlation with uric acid (r=0.527, 
p=0.006) (Fig. 2), but serum NO levels did not correlate posi-
tively with uric acid, insulin or QUICKI. These correlations 
were not observed in the HTN without MS group. Multiple 
linear regression analysis with serum adiponectin and RBP4 
levels as the dependent variables revealed that only uric acid 
Table 1. Clinical characteristics and metabolic variables of hyper-
tensive patients with or without metabolic syndrome
MS (-) n=12 MS (+) n=26 p
Age (years) 49±9 0 48±80 0.947
Sex (M/F) 5/7  12/14  0.800
BMI (kg/m
2) 23.2±1.80 25.9±3.20 0.012
Waist (cm) 84.9±4.90 89.9±6.00 0.012
Sys. BP (mmHg) 150±130 147±140 0.539
Dia. BP (mmHg) 98±10 100±100 0.558
Heart rate (/minutes) 68±68 72±15  0.106
Fasting glucose (mg/dL)  93±9 0 96±90 0.306
HbA1C (%) 5.5±0.4  5.5±0.4  0.755
Creatinine (mg/dL) 0.8±0.2 0.8±0.2 0.850
Total cholesterol (mg/dL) 209±38 0 207±410 0.878
Triglyceride (mg/dL) 103±430 165±760 0.012
HDL-C (mg/dL)  53±10 43±80 <0.001
Spot urine MCR (mg/g) 43±40 071±220 0.094
hs-CRP (mg/dL) 1.79±2.71  2.21±6.85 0.848
Fibrinogen (mg/dL) 282±77 324±540 0.111
Uric acid (mg/dL) 4.13±1.26 5.03±1.19  0.040
Insulin (µU/mL) 4.6±2.5  6.8±3.5 0.129
QUICKI 0.39±0.04 0.37±0.04 0.099
RBP4 (μg/mL) 21.3±12.6 38.4±29.7 0.106
Adiponectin (µg/mL) 8.57±6.58 4.53±4.31 0.030
Nitric oxide (µmol/mL) 61.2±36.0 27.5±22.5 0.003
BMI: body mass index, BP: blood pressure, HDL-C: high density-li-
poprotein-cholesterol, MCR: microalbumin to creatinine ratio, hs-
CRP: high sensitivity C-reactive protein, QUICKI: quantitative in-
sulin sensitivity check index, RBP4: retinol-binding protein 4
Table 2. Correlation between classical and novel biomarkers in hypertensive patients with or without metabolic syndrome
UA Adiponectin RBP4 NO
MS (-)
UA
Pearson 
  product-moment
  correlation 
  coefficient
1
Adiponectin -0.482 1
RBP4 -0.247 -0.339 1
NO -0.088 -0.370 -0.438 1
MS (+)
UA
Pearson 
  product-moment
  correlation 
  coefficient
1
Adiponectin -0.413* 1
RBP4 -0.527† -0.113 1
NO -0.243 -0.149 -0.286 1
*Correlation is significant at the 0.05 level, †Correlation is significant at the 0.01 level. MS: metabolic syndrome, UA: uric acid, RBP4: retinol 
binding protein 4, NO: nitric oxide
Fig. 1. The relationship between the plasma adiponectin and uric 
acid in the hypertensive patients with metabolic syndrome.
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Fig. 2. The relationship between the plasma RBP and uric acid in 
the hypertensive patients with metabolic syndrome.
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correlated independently with serum RBP4 and adiponectin 
level (Table 3 and 4).
Discussion
We have presented a correlation between the two types of 
adipokines (adiponectin and RBP4) and uric acid in the HTN 
with MS group. RBP4 had a positive correlation with uric 
acid, while adiponectin had an inverse correlation with uric 
acid. In addition, we also demonstrated that the HTN with 
MS group had significantly higher values of serum uric acid 
and lower serum adiponectin and NO levels than the HTN 
without MS group. The strength of this study was that the sub-
jects were initially diagnosed as HTN had not taken any me-
dications; thus there were no confounding factors such as anti-
hypertensive, anti-diabetic and lipid-lowering agents which 
are known to affect cytokine levels. Secondly, we used multi-
ple linear regression analysis to confirm the association be-
tween the two adipokines (adiponectin or RBP4), NO and 
uric acid, which are the known risk factors of MS and cardio-
vascular events in HTN accompanying MS. 
Our study also showed that the levels of serum uric acid 
were elevated in the HTN with MS group. Hyperuricemia is 
related to an increased incidence of high BMI, high BP, high 
triglycerides and a 10-year probability of coronary heart dis-
ease.
6)12) It is also associated with insulin resistance and its me-
chanism is a decreased renal excretion of uric acid.
13)14) 
Increased serum RBP4 levels were known to contribute to 
impaired insulin-stimulated glucose uptake in muscle and 
elevated hepatic glucose production, both of which are char-
acteristic of type 2 diabetes.
9) RBP4 level is currently known 
to be independently associated with uric acid level in pa-
tients with type 2 diabetes mellitus.
15) Our data showed that 
serum RBP4 levels were elevated in the HTN with MS group, 
but was not significantly different than in the HTN without 
MS group (p=0.106). However, RBP4 was strongly correlated 
with uric acid which was a cardiovascular risk factor and a 
determinant of MS.
6) The levels of two types of adipokines 
(adiponectin and RBP4) showed a significant relationship with 
uric acid in the HTN with MS group and it was stronger be-
tween RBP4 and uric acid. Only RBP4 levels showed a inde-
pendent relationship with uric acid after multivariate regres-
sion analysis when considering for age, BMI, creatinine, total 
cholesterol and QUICKI. Elevated plasma levels of RBP4 are 
known to be related with cerebrovascular disease and meta-
bolic complication.
16) 
In our study, serum adiponectin levels were decreased in 
the HTN with MS group as compared to the HTN without 
MS group. Adiponectin levels also correlated with uric acid, 
but this relationship was weaker than the relationship between 
RBP4 and uric acid. In contrast to the other adipocyte-derived 
proteins, adiponectin has anti-inflammatory and anti-athero-
genic activities. Low levels of adiponectin are considered as a 
hallmark of MS and increases the risk of insulin resistance, 
visceral adipocity and related MS.
17) The plasma levels of NO 
were significantly different between the two groups. But NO 
failed to exhibit a relationship with the other clinical or bio-
chemical markers of hypertension with MS. It may be due to 
its labile character and a relatively small number of patients 
in this study. 
The limitations of our study are a cross-sectional design and 
small sample size. Large, prospective, placebo-controlled in-
tervention trials are needed to document whether changing the 
levels of the two types of adipokines (adiponectin and RBP4) 
or uric acid by pharmacological treatment might lead to a 
reduced risk for cardiovascular event. 
In conclusion, plasma levels of the two types of adipokines 
(adiponectin and RBP4) and uric acid showed a correlation 
in the HTN with a complication of MS group. This result can 
add further evidence of RBP4 as a marker of metabolic com-
plication in addition to adiponectin, especially in the HTN 
patients.
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